Roche agreed to develop a weight-loss drug with Danish biotech Zealand Pharma, pressuring Novo Nordisk and Eli Lilly.

The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

The news sent Roche's stock up more than 4% in trading Wednesday, and Zealand's stock skyrocketed 40% on the news. Meanwhile, Novo Nordisk's stock was hit, sliding 4%, and Eli Lilly's stock was down ...

Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its ...

Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...

Germany's financial markets watchdog is looking at whether Bayer fairly disclosed plans for shareholder approval of a capital ...

Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...

Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand Pharma’s obesity drug candidate.

Roche Holding AG licensed a new weight-loss drug from Zealand Pharma A/S for as much as $5.3 billion, bolstering the Swiss ...

Novo Nordisk announced a direct-to-consumer program that allows patients to buy Wegovy out of pocket at a lower cost.

Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for GLP-1s and ...